Index Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 27, 2026

Across 50 SEC filings from the S&P 500 Consumer Discretionary stream (broadly encompassing retail, auto, and adjacent sectors amid mixed inclusions), Q1 2026 earnings reveal resilient net income growth in financials and select industrials (e.g., Lakeland +32% YoY, Bank of Hawaii +30.6% YoY) with NIM expansions averaging +7bps across reporting banks, offsetting margin pressures elsewhere; revenue trends mixed with outliers like Solaris +55% QoQ but Kforce flat YoY. M&A momentum accelerates with BioMarin $4.8B Amicus close, multiple bank mergers (Flushing/OceanFirst by June 1) securing approvals, and Tesla registering 304M shares for Musk's 2018 award signaling milestone achievement. 13F portfolios (15+ filings) show extreme concentration in mega-tech (AAPL, MSFT, AMZN, NVDA topping most), underscoring conviction amid Consumer Discretionary volatility. Capital allocation favors returns (Kforce $11.7M repos + $6.8M divs; Solaris $0.12 div), but cash burn widens losses in biotech/energy (Fulcrum -$18.9M). Guidance mostly raised/issued (Solaris Q2 EBITDA $83-93M up from prior), building Q2 catalysts; sentiment mixed (18/50), with portfolio-level margin stability but deposit/loan softness in banks.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 27, 2026

Across 50 SEC filings from the USA S&P 500 Healthcare stream (though heavily skewed to financials/banks with limited pure healthcare), key themes include mixed Q1 2026 results with YoY net income surges (Lakeland Financial +32% to $26.5M, Cincinnati Financial swing from -$90M to +$274M, HBT adjusted +12.4% QoQ) offset by QoQ declines and merger costs, accelerating M&A with full regulatory nods for OceanFirst/Flushing (close by June 1) and HBT/CNB completed adding $1.8B assets. Healthcare highlights feature Sagimet Biosciences' strong partner Phase 3 acne data (33.2% success vs 14.6% placebo, US Ph3 2H26), Medtronic's contained cyber incident (no material impact expected), and strong proxy approvals at Pfizer/Cigna (94-98% director support). Capital allocation trends bullish with share repurchases ramping (Waterstone +2M shares auth to 2.1M avail, FB Financial $175M renewed thru 2027, Lakeland $21.2M remaining, Cincinnati $179M Q1) and dividend hikes (Cincinnati +8% to $0.94/share). Forward-looking catalysts cluster in June (mergers, AGMs), while 13F filings reveal broad ETF/stock holdings neutral. Portfolio-level, financials drive consolidation/returns themes, healthcare shows biotech promise amid cyber/governance risks; actionable now: buy merger arb plays, monitor deposit trends.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 24, 2026

Across 27 filings in the USA S&P 500 Technology intelligence stream, proxy season dominates with 15+ DEF 14A/DEFA14A disclosures signaling upcoming AGMs in May-June 2026 as key catalysts for governance votes, equity plan expansions, and say-on-pay approvals (e.g., Acadia May 29, Block June 16). Q1 2026 financials show stark divergence: Texas Instruments (TXN) delivered blowout growth with revenue +18.6% YoY to $4.8B, net income +31% to $1.5B, and op cash flow +79% to $1.5B, contrasting Charter Communications' -1% YoY revenue decline to $13.6B amid video revenue -9.1%. Institutional 13F filings (Muzinich, Semus, United Community Bank, Squire) reveal persistent conviction in mega-cap tech leaders like AAPL ($34M-$4B positions), NVDA ($7.5M+), MSFT, AMZN, underscoring portfolio concentration in growth tech. Capital allocation remains shareholder-friendly with TXN's $1.3B Q1 dividends, FHLB's $75M special dividend, Genco's record $0.50/share, and Charter's buybacks boosting EPS +7.9% despite NI drop. Mixed sentiment prevails (9 mixed, 13 neutral, 3 positive), with no major insider selling but positive exec comp beats (Immunome bonuses 145-150% of target). Forward catalysts include Altimmune's Phase 3 MASH trial funding from $211M raise and Genco's proxy battle. Overall, tech sector shows resilient institutional demand and semi strength amid broader mixed trends, favoring longs in outperformers like TXN.

13 high priority 14 medium 27 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 24, 2026

Across 33 filings from NASDAQ-100 related entities, proxy statements dominate (18/33) signaling peak annual meeting season in May-June 2026, with positive executive comp and achievements in biotech/tech (e.g., Immunome exceeded targets 145-150%, Alphabet Gemini launch). Q1 2026 financials show semis rebounding (Intel rev +7.2% YoY to $13.6B, TI +18.6% to $4.8B) amid CHIPS incentives, but mixed elsewhere: telecom softness (Charter rev -1% YoY), coal disruptions (Alpha Met Q1 loss $11M), and sharp declines (ILAG rev -40.1% YoY). Capital returns strong (Comcast $11.7B buybacks/divs reducing shares 5%, TI $1.29B divs), with biotech funding wins (Altimmune $211M for Phase 3 MASH trial). Portfolio trends: Revenue growth avg +10% YoY in reporting cos (5/7), but losses prevalent (Intel $3.7B net loss, Blue Moon $38.8M); positive sentiment 12/33, mixed 10/33. Key implications: Watch proxy votes for equity plan approvals adding shares (Alphabet 200M Class C), semis for foundry ramps, biotechs for catalysts.

16 high priority 17 medium 33 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 24, 2026

The 50 filings in the USA S&P 500 Financials intelligence stream reveal a mix of proxy statements (20+ filings, neutral sentiment) for June 2026 AGMs focusing on director elections, auditor ratifications, and exec comp approvals, alongside 20+ 13F-HR snapshots from asset managers showing heavy tech overweight (Apple, NVDA, AMZN top across portfolios) but notable financials exposure (Visa $134M top at Ninety One, JPM $32M at Alley, BDCs like Ares $40M at Muzinich). Period-over-period trends highlight strong revenue growth in financials/fintech (UP Fintech +56.3% YoY to $612M, First American +16.2% YoY to $1.84B) averaging +30% YoY across growth reporters, but mixed profitability (Flagstar Q1 NI turnaround from -$100M YoY loss to +$21M, yet NII -5% QoQ). Margin compression evident in non-financials (Gravity gross margin -370bps to 35%, Medicure gross profit -10% despite +32% rev), with capital allocation favoring returns (First Am $33.5M buybacks + $56M dividends Q1, News Corp $1B ongoing buyback). No widespread insider trading patterns, but regulatory risks loom (UP Fintech delisting threat). Implications: Bullish on recovering banks/insurers, watch proxy votes and fintech regs for near-term catalysts.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 24, 2026

Across 50 SEC filings for the USA S&P 500 Consumer Staples intelligence stream (despite broader coverage including tech/industrials), key themes include mixed Q1/FY26 earnings with revenue growth averaging +8% YoY in reporters like Procter & Gamble (+7% Q3 sales to $21.2B, organic +3%), Philip Morris (+9.1% to $10.1B), Intel (+7.2%), and Sibanye Stillwater (+15.6%), but persistent margin compression (e.g., P&G core gross -100bps, op -80bps) and earnings volatility from one-offs/restructuring. Proxy season dominates with 20+ AGMs clustered in June 2026, featuring director elections, say-on-pay, equity plan expansions, and governance tweaks like bylaws (JPM, Kontoor). 13F-HR filings (12 total) reveal institutional portfolios heavily tilted to tech megacaps (e.g., Chicago Capital $187M Alphabet, Sumitomo $592M Apple), signaling rotation away from staples amid neutral sentiment. Capital allocation emphasizes dividends (PMI +9% to $1.47/share, Sibanye 131cps) and buybacks (Charter EPS +7.9% via repurchases), with forward catalysts like Honeywell Aerospace spin (3Q26) and Elmet IPO ($120M proceeds). Portfolio-level trends show 5/10 earnings reporters with YoY rev growth >7% but 7/10 with op margin declines avg -50bps, highlighting cost/tariff pressures; actionable now: favor staples with volume growth (P&G Beauty +7%) over volume decliners.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 24, 2026

Across 50 SEC filings from April 24, 2026, primarily 13F-HR holdings reports (25+), proxy statements (10+), and quarterly/annual financials (10+), overarching themes include peak proxy season with strong shareholder support in AGMs, institutional portfolios overwhelmingly tilted to tech/AI giants (Alphabet, Nvidia, Apple topping 80% of 13Fs), and mixed financial performance in reporters with average revenue growth +8.4% YoY across 12 firms (e.g., Sibanye +15.6%, Philip Morris +9.1%) but profitability challenges (5/12 saw net income declines, avg -5.2%). Industrials-relevant signals shine: Trane Technologies expands $1.5B credit facility signaling liquidity for growth; AITX secures construction-site AI orders; Defense Tech cash burn persists. M&A in Peoples Bancorp offers accretion potential spilling into sector stability; urban-gro defaults highlight credit risks. Portfolio-level: No insider trading patterns (absent in filings), capital allocation favors dividends (Sibanye 131 cps, PMI +9% div), with upcoming AGMs as catalysts for equity plan approvals and comp votes.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 24, 2026

Across 19 filings in the S&P 500 Energy stream, energy services and midstream firms show mixed Q1 2026 results: revenues grew modestly (SLB +3% YoY, Baker Hughes +2.5% YoY, Kinder Morgan +14% YoY) while Halliburton dipped -0.3% YoY, but net income surged dramatically (Baker +131% YoY to $930M, Halliburton +128.6% YoY to $464M, Kinder +36% YoY to $976M) driven by one-time gains and absent impairments. Devon Energy's merger with Coterra advances amid lawsuits, with supplemental DCF fairness opinions valuing Devon at $37.50-$54.97/share (vs $39.45 close) and meetings set for May 4, 2026. Capital allocation remains shareholder-friendly with SLB's $0.295/share dividend (payable July 9), Kinder's $654M dividends paid, and Baker's cash ballooning to $14.8B post-debt issuance. Non-energy filings (13Fs, REITs, tech) reveal neutral institutional positioning in tech/banks/ETFs with no energy tilt, while SLB announces M&A (OneSubsea/Envirex H1 2026, S&P software H2 2026). Portfolio-level trends indicate improving profitability (avg +98% YoY NI across core energy filers) despite sequential declines (SLB rev -11% QoQ), signaling resilience amid Middle East disruptions but vulnerability to one-offs. Key implication: tactical opportunities in merger arb and services recovery, watch May catalysts.

5 high priority 14 medium 19 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 24, 2026

Across 50 filings from Dow Jones 30-related and adjacent streams, Q1/FY2026 earnings show mixed results with top-line growth in 6/12 key reporters (avg +6% YoY revenue: PG +7%, Intel +7.2%, SLB +3%, Sibanye +15.6%) offset by pervasive margin compression (avg -100bps: PG -150bps gross, Gravity -370bps gross, SLB adj EBITDA -12%) due to costs, tariffs, and reinvestments. Portfolio transformations dominate industrials (Honeywell Aerospace spin 3Q2026, Solstice completed Oct2025), while telecom/cable faces subscriber erosion (Charter internet -120k, total relationships -1.5% YoY). Institutional 13F-HR filings (17/50) reveal heavy tech concentration (AAPL, AMZN, GOOGL, NVDA top across ProCore, Q Fund, IFM, etc.), signaling conviction in mega-caps amid volatility. Proxy season ramps with 10+ AGMs in June 2026 (VAALCO Jun4, Live Nation Jun11, Vertiv Jun17), focusing on comp, auditors, and share increases. Capital allocation leans defensive (PG adj FCF productivity 82%, SLB div $0.295, ChoiceOne cap ratio 12.9%), but dilution risks loom (MicroVision 61M shares resale). Implications: Favor resilient consumer staples and tech holdings; trim margin-challenged cyclicals like chems/energy.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 24, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary intelligence stream (though heavily featuring financials, SPACs, and 13Fs), key themes include YoY earnings recovery in financials (avg net income +50-180% in 7 reporters like LVS +61%, UP Fintech +179%) offset by QoQ softness (e.g., Ponce -16%, Flagstar down), heavy institutional conviction in mega-cap tech (Apple, Nvidia, Amazon topping 25+ 13Fs), and clustered proxy events for AGMs/share votes in May-June. Aggregate trends show revenue surges (LVS +25% YoY, FAF +16%, UP +56%) with mixed NIM (expansions like Ponce +63bps YoY, compressions elsewhere), deposit/loan growth (avg +2-5% QoQ where reported), and active capital returns ($746M LVS buybacks, $33M FAF repurchases, FBIZ div +17%). No dominant insider trading patterns, but high ownership alignment (Lifetime Brands group 44.4%). Critical developments: Nasdaq delist risks (SHF), PRC regs (UP Fintech), M&A advances (Woori, Willow Lane). Implications: Bullish on gaming/fintech growth plays, caution on small-cap compliance/litigation, monitor AGMs for governance shifts amid tech-heavy portfolios signaling defensive positioning.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 24, 2026

Across 50 filings dated April 24, 2026, primarily from financial institutions and a handful of S&P 500 Healthcare names, Q1 2026 bank earnings dominate with mixed results: 7/10 banks showed YoY net income growth or turnarounds from losses (avg +25% YoY) but QoQ declines in 6/7 (avg -15%), driven by NIM expansions (avg +40bps YoY) offset by higher expenses and softer loan growth (avg -1% QoQ). Healthcare filings reveal positive funding momentum with Citius Pharma raising $5M for LYMPHIR launch, Lucid Diagnostics closing $16.8M offering, and Regeneron highlighting $14.3B 2025 revenues with $3.8B shareholder returns, contrasting neutral biotech proxies (Caribou, Rallybio). 20+ 13F-HR filings indicate portfolio managers overweight ETFs/tech (e.g., Apple, Nvidia top holdings across 15/20), with healthcare exposure in Amicus, Abbott, Masimo via select funds. Capital allocation trends favor buybacks/dividends (e.g., $33.5M repurchases at First American, $75M special dividend at FHLB SF), signaling confidence amid asset quality improvements (NPLs down in 4/7 banks). Key implication: Banking recovery YoY supports healthcare-adjacent stability, but QoQ softness flags deposit/loan pressures; monitor June biotech AGMs for governance catalysts.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 23, 2026

Across 26 filings from S&P 500 Technology stream and related sectors, Q1 2026 results reveal mixed performance with strong revenue growth in tech names (avg +17% YoY for ServiceNow +22%, Lam Research +23.8%, IBM +9%, Knowles +16%) offset by expense pressures and flat incomes, while banks show NIM expansions (e.g., Dime 3.21%, Amalgamated +9bps to 3.75%) but rising provisions/NPLs (Amalgamated NPA to 1.08%, Dime NPL $57.1M). Capital allocation favors shareholder returns via buybacks (ServiceNow $2.225B, Lam $3.6B treasury), dividends (Esquire +14% to $0.20, Community West $0.12), and debt management (CHS tender $600M notes). M&A catalysts cluster in Q2 2026 (Pershing Vantage close, multiple bank mergers), with forward guidance stable (Iridium FY service flat-+2%, Knowles Q2 $152-162M rev). Portfolio trends highlight tech outperformance vs financials' credit risks, with 14/20 Q1 reporters mixed sentiment due to YoY income volatility despite top-line gains. Key implication: Rotate into high-growth tech amid bank margin resilience but watch credit deterioration.

10 high priority 16 medium 26 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 23, 2026

Across 28 filings from NASDAQ-100 and related constituents on April 23, 2026, banking names dominate with mixed Q1 results showing YoY net income growth averaging ~40% (e.g., Richmond Mutual +40%, Dime +67%, Community West +38.6%) driven by NIM expansion (e.g., Amalgamated +9bps to 3.75%, Dime to 3.21%, Community West to 4.30%), but offset by rising provisions/NPLs (Amalgamated NPA to 1.08%, Dime NPL $57.1M). Tech/media leaders like Comcast (revenue +5.3% YoY), Tesla (revenues +16% YoY, gross profit +50%), Lam Research (revenue +23.8% YoY), and Intel (revenue +7% YoY) report solid top-line growth amid content/events, but earnings pressure from costs/restructuring; bullish capital returns surge with Netflix's $25B buyback, T-Mobile's $3.6B program increase to $18.2B, Comcast $1.3B repurchases, and Lam $3.6B treasury buys. Homebuilders like Century Communities face headwinds with revenue -12.6% YoY. Portfolio-level trends highlight NIM resilience vs credit deterioration in banks (6/9 banks with higher provisions/NPLs), robust buybacks/dividends signaling confidence (7 companies announcing/expanding returns), and reiterated guidance (Iridium FY OEBITDA $480-490M, Keurig FY sales $25.9-26.4B). Mergers advance (Richmond/Farmers Q2 close, Community West completed Apr 1), creating M&A catalysts. Overall, mixed sentiment (17/28 mixed) points to resilient growth but credit/opex risks, favoring capital return plays amid stabilizing macros.

11 high priority 17 medium 28 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 23, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (broadly including banks, insurers, and related services, with some cross-sector overlaps), Q1 2026 results show robust revenue growth averaging 10-15% YoY in 70% of quarterly reporters (e.g., Tesla +16%, Thermo Fisher +6%, PG&E +15%), driven by acquisitions and pricing, but offset by margin compression in 60% (avg -50-150 bps) from higher opex/depreciation and impairments. Capital allocation remains a bright spot with aggressive buybacks (Netflix +$25B, Thermo Fisher $3B, Waste Connections $284M) and dividend hikes (Texas Capital initiates $0.20, CenterPoint guidance intact). Financials-specific trends include NIM expansion/stability (CVB +13 bps YoY to 3.44%, TriCo +5 bps to 4.07%) amid loan growth (Southern Missouri +7.4% YoY), but rising provisions/charge-offs signal credit stress. Forward-looking guidance mostly reaffirmed (Honeywell 3-6% organic growth, PG&E $1.64-1.66 EPS), with M&A/tenders (Capital One Brex, Community Health $600M notes) and equity raises indicating balance sheet maneuvers. Portfolio-level: 8/10 high-materiality filings bullish on returns, mixed earnings highlight resilience but watch credit/opex. Key implication: Favor capital return plays over pure growth amid macro uncertainty.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 23, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Staples intelligence stream (including adjacent sectors), Q1/FY2026 earnings reveal mixed performance with revenue growth averaging +8% YoY in 12 reporting companies (e.g., Mobileye +27%, Keurig Dr Pepper +9.4%, Thermo Fisher +6%), but frequent non-cash impairments (Helen of Troy $886M, Mobileye $3.8B) drove EPS declines in 60% of cases. Capital allocation remains robust, with $30B Walmart buyback authorization, $6B Newmont repurchase, $3B Thermo Fisher repurchases, and dividend hikes (Thermo Fisher +10%, PG&E core EPS guidance $1.64-$1.66 reaffirmed). M&A activity surges (Thermon/CECO merger HSR cleared Apr 2, Helix/Hornbeck announced Apr 22, Masimo/Danaher vote May 1), alongside proxy-heavy calendar for June 2026 annual meetings (20+ filings). Consumer Staples outliers show Walmart's superior cash flow ($41.6B) and profits outpacing sales vs. Helen of Troy's -6.4% sales drop and margin contraction (-400bps Q4 gross). Portfolio trend: Margin expansion in 4/10 earnings (Honeywell +90bps), compression in 5/10 (avg -150bps); strong FCF supports returns amid flat guidance changes. Implications: Favor buyback-heavy names for near-term yield; monitor June catalysts for governance/M&A risks.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 23, 2026

Across 50 SEC filings from S&P 500 Industrials and adjacent sectors on April 23, 2026, Q1 2026 results dominate with mixed sentiment (25/37 scored mixed), revealing YoY revenue growth averaging ~10% in industrials (e.g., Gentherm +11.3%, Mobileye +27%, Honeywell +2% organic) but banking pressures from rising credit provisions (e.g., NBT +$5.6M, Texas Capital $16M) and NIM volatility (expansions like NBT +28bps, compressions like First Citizens -11bps). Margin expansions noted in 8/15 reporting firms (avg +100bps, e.g., Gentherm EBITDA +140bps), offset by impairments (Mobileye $3.8B goodwill) and operational declines (Lockheed cash flow -84% YoY). Capital returns strong with buybacks ($6B Newmont, $250M Mobileye) and dividend hikes (Patterson-UTI +to $0.10, Texas Capital inaugural $0.20), while M&A catalysts abound (Gentherm-Modine HSR cleared, L3Harris $1B DoD investment). Portfolio-level trends show 12/20 banks with deposit growth (avg +10% annualized) but loan declines in 7/15 (avg -1% QoQ), signaling caution amid credit deterioration (NPAs up in 9 firms). Forward guidance largely maintained/raised (e.g., PECO Core FFO +5.8%, West Pharma sales +7-9%), building Q2 catalysts; defense/industrials resilient amid geo-tensions.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 23, 2026

Across the five filings in the USA S&P 500 Energy intelligence stream, sentiment is predominantly mixed with positive financing activity in Idaho Copper offset by revenue declines and sequential weakness in Robert Half and Baker Hughes. Key period-over-period trends reveal YoY revenue divergence: Baker Hughes +2% YoY to $6.6B despite -11% QoQ, Robert Half -4% YoY to $1.3B, Dorchester Minerals steady royalty receipts at $26.6M with oil at $51.79/bbl and gas $2.27/mcf. Capital allocation highlights shareholder returns via Dorchester's $0.475/unit Q1 2026 distribution (record date May 4, pay May 14) and Baker's divestitures targeting ~$3B proceeds in 2026, while Idaho Copper raised $1.36M in convertible notes for growth. No insider trading activity reported across filings, but strong Baker orders (+26% YoY to $8.2B, record IET RPO $33.1B) signal sector resilience amid Middle East disruptions. Portfolio-level patterns show energy services and royalties holding up better than adjacent staffing, with low oil realizations pressuring margins; actionable implications include monitoring Q2 catalysts for turnaround in sequential trends.

1 high priority 4 medium 5 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 23, 2026

The 50 filings for USA Dow Jones 30 stream (April 23, 2026) are dominated by Q1 2026 earnings from ~25 financial institutions and industrials, revealing YoY net income growth averaging ~25% across banks (e.g., OP Bancorp +30%, Bread Financial +32%) but QoQ declines in 70% of cases due to higher provisions and NIM compression (avg -5-10 bps QoQ). Revenue trends strong YoY (+10-20% in tech/industrials like ServiceNow +22%, IBM +9%, Dover +10%) but sequential softness amid supply chain/Middle East issues. Capital allocation robust with buybacks (e.g., First Citizens $900M, Mobileye $250M) and dividend hikes (e.g., ConnectOne +8.3%, Texas Capital initiated $0.20). Mixed sentiments prevail (80% mixed/neutral), with positive outliers in consumer finance (AmEx +15% NI) and credit (Bread Financial delinquency -34 bps). Forward guidance mostly reaffirmed/raised (e.g., Mobileye +2% rev, PG&E $1.64-1.66 EPS), signaling stability; M&A active (e.g., CVB Heritage close April 17, Richmond-Farmers Q2). Portfolio-level: Banks show deposit growth (avg +2-5% QoQ) offsetting loan stagnation/NPL rises (avg +20-30% QoQ), industrials divest for focus (Baker Hughes ~$3B proceeds). Implications: Tactical buys in resilient banks/tech, caution on credit risks, monitor June catalysts for blue-chips.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 23, 2026

Across 50 SEC filings from April 23, 2026, primarily Q1 2026 results and proxy/M&A disclosures, financial institutions dominate with mixed performance: average loan growth ~2-5% QoQ/YoY in 10+ banks (e.g., First Citizens +0.5% loans, +5.7% deposits), but NIM compression in 6/12 reporters (avg -7bps QoQ, e.g., First Citizens -11bps) offset by strong capital returns ($900M buybacks at First Citizens, $617M at Hartford). Consumer Discretionary standouts include Tesla's +16% YoY revenue to $22.4B (automotive +20%) and Netflix's $25B buyback authorization atop $6.8B remaining, signaling conviction amid sector sales declines (Helen of Troy -6.4% FY26 YoY, massive $886M impairments). M&A activity surges with premiums (Webster +16% at $75.63/share) and closures (CVB Heritage Apr 17, Capital One Brex Apr 7), while capital allocation favors shareholders (12+ dividend hikes/buybacks, e.g., Bread +$600M authorization). Sentiment mixed (18/50), with portfolio trends showing revenue growth avg +8% YoY in reporters but margin pressure (-50bps avg in 7 firms) and rising provisions/NPAs in banks. Implications: Favor buyback-heavy names for near-term support, monitor NIM/asset quality for financials, and eye Helen turnaround via FY27 guidance ($1.75-1.82B sales). Actionable now: Accumulate Netflix/Tesla on growth/cash return strength.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 23, 2026

Across 50 filings dominated by financial institutions (30+), Q1 2026 results show YoY net income growth averaging +25% in outperformers like Franklin Financial (+69%) and Univest (+25%), but QoQ declines in 6/12 banks (avg -6%), with NIM mixed: expansions +13-48bps YoY in CVB/Franklin vs compressions -5-11bps QoQ in CVB/First Citizens. Healthcare/biotech filings (8: Edgewise, Caris, Thermo Fisher, Minerva, SELLAS, Solid, Inhibrx, Lifeward) are mostly neutral proxy statements for June 3-16 annual meetings, lacking financial trends but highlighting governance enhancements. Capital allocation bullish: 10+ firms hiked dividends (avg +8%, e.g., Esquire +14%, Principal +8%), repurchases total $12B+ (Newmont $6B auth, Thermo $3B executed, Bread $690M auth), signaling conviction amid $200B+ deposit/loan growth QoQ. M&A active: GCI $310M Quintillion (healthcare wholesale support), CVB Heritage completion Apr17, Axos IRA from Capital One, Burke & Herbert LINKBANCORP May1 close. Forward guidance stable/positive (Bread low-single digit growth/7.2-7.4% loss rate; Newmont 5.3M oz gold), but mixed sentiment (18/50) from provision hikes/NPA rises. Portfolio trend: Banks ROA/ROE 1.2-1.4%/12-16%, provisions up YoY signaling credit stress; healthcare routine, no major catalysts. Implications: Buy dividend growth banks, monitor NIM/provisions for rotation; biotech proxies low alpha unless share increases pass (Solid +100% auth shares).

11 high priority 39 medium 50 total filings